Bifogade filer
Nanoform financial calendar for 2026
Nanoform Finland Plc | Press Release | December 30, 2025 at 11:00:00 EET
Helsinki, Finland – In this announcement Nanoform provides its financial calendar for 2026, which include the planned publication dates of its financial reports, annual report and annual general meeting.
Planned publication dates for Nanoform's financial reports:
- report for Q4 2025 and full year 2025: February 26th, 2026
- report for Q1 2026: May 19th, 2026
- report for Q2 2026 and half-year 2026: August 20th, 2026
- report for Q3 2026 and January-September 2026: November 11th, 2026
- report for Q4 2026 and full year 2026: February 25th, 2027
Nanoform plans to publish its Annual Report for the year 2025, which includes the review by the Board of Directors and the audited annual accounts, latest end of March 2026.
Nanoform’s Annual General Meeting 2026 is planned to be held April 14th, 2026.
For further information, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com / +46 76866 50 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.